Molecular diagnostics developer INEX Innovate announces funding for new research with the Chinese University of Hong Kong


SingaporeINEX Innovate, developer of diagnostics based on the Chinese University of Hong Kong together to continue research on LEXI®, INEX’s non-invasive prenatal diagnostic technology based on fetal cells.

SINGAPORE, July 26, 2022 /PRNewswire/ — SingaporeINEX Innovate, a diagnostics developer and medical laboratory operator, has contributed an undisclosed sum to the leader Hong Kong University – The Chinese University of Hong Kong (CUHK), to collaborate and pursue research in the field of maternal-fetal medicine.

INEX’s Dr Chia-Pin Chang with Professor Richard Choy of the Chinese University of Hong Kong

The Department of Obstetrics and Gynecology (O&G) at CUHK is recognized globally for its many leading contributions and high-impact publications in the scientific community, attributed to its pursuit of advancing O&G knowledge through research. clinical, scientific and translational. This initiative will leverage CUHK’s research expertise to advance LEXI®, a novel fetal cell isolation technology developed by INEX Innovate.

LEXI® is a non-invasive prenatal diagnostic (NIPD) technology that isolates fetal cells from the unborn baby, contained in the pregnant mother’s blood for definitive analysis of over 7,000 potential rare fetal genetic diseases.

Currently, pregnant women whose prenatal screening results show signs of fetal abnormality are often recommended to undergo prenatal diagnostic testing for a definitive diagnosis of fetal genetic abnormalities, as this allows for early medical treatment of these conditions. However, common diagnostic procedures such as amniocentesis are invasive and carry a risk of pregnancy loss of up to about 5%.[1].

Developed by INEX Chief Technology Officer Dr. Chia Pin Chang, LEXI® Cell Isolation and Enrichment is a process that isolates, identifies and extracts target cells such as fetal cells from blood samples. The LEXI® microfluidic chip enables its microfabricated filter to successfully deplete most non-target cells in a blood sample and effectively capture fetal cells. Clinicians will need to take a tube of blood from a pregnant woman to generate results on the health status of the fetus.

Managing Director of INEX Innovate, Black Kane said: “We are delighted to support and further LEXI®’s research with Professor Richard Choy and his team at Chinese University of Hong Kong (CUHK), the pioneering center of scientific excellence that focuses on translating research advances into clinical impact both locally and internationally.

Mr Black added that fetal cells in maternal blood represent the holy grail of prenatal diagnosis. The major challenge has been the isolation of these cells from maternal blood due to their rarity, we look forward to working on this potentially cutting-edge medical breakthrough with CUHK..

“We look forward to developing potentially important breakthrough technology in the field of maternal-fetal medicine,” said Professor Choy, Department of Obstetrics and Gynecology at The Chinese University of Hong Kong.

[1] Cynthia L. Anderson, MD, and Charles EL Brown, MD, MBA, “Fetal Chromosomal Abnormalities: Prenatal Screening and Diagnosis, American Family Physician, 2009 Jan 15;79(2):117-123.

About INEX Innovate:

INEX Innovate is one of from Asia fastest growing molecular diagnostics developers and medical laboratory operators.

Founded by seasoned maternal-fetal medicine specialists, INEX is uniquely positioned to identify and address clinically unmet needs in the fetal health and female oncology landscape, with a broad commercial portfolio of validated tests and 48 key patents.

Through our wholly-owned subsidiary iGene Laboratory Pte Ltd, INEX operates a state-of-the-art next-generation sequencing laboratory that provides diagnostic testing, clinical research (CRO) and COVID-testing services. 19.

The company has been recognized worldwide with a number of accolades and awards including Frost & Sullivan, World Intellectual Property Organization (WIPO), Straits Times – that of Singapore Fastest growing companies and the Financial Times 500 ranking Asia Pacific Fastest growing companies.

For more information, please visit:

About Chinese University of Hong Kong (CUHK):

Founded in 1963, CUHK is a leading comprehensive research university with a global reputation. Located in the heart of AsiaCUHK has a vision and a mission to combine tradition and modernity, and to bring together China and the West. As part of the University’s unique college system, the programs and activities offered by its nine colleges complement formal programs by providing whole-person education and pastoral care. The University has eight faculties: Arts, Business Administration, Education, Engineering, Law, Medicine, Science, and Social Science. Together with the Graduate School, the University offers more than 300 undergraduate and postgraduate programs. All faculties are actively engaged in research in a wide range of disciplines, with a range of research institutes and research centers specializing in interdisciplinary research of the highest quality.

The University currently has more than 1,400 patents issued in different jurisdictions around the world. Some of these patents have been licensed to relevant industries that help bring these innovations to market for the benefit of society. In the 2020-21 academic year, CUHK received 226 granted patents and filed 386 patent applications for inventions developed in the fields of medical technology, biotechnology, information technology, telecommunications and materials science.

Source link


Comments are closed.